Thrombotic microangiopathy associated with use of interferon-beta

ombotic microangiopathy associated with use of interferon-beta Case report (1467) Total Article Views Authors: Olea T, Diaz-Mancebo R, Picazo ML, Martinez-Ara J, Robles A, Selgas R Published Date June 2012 Volume 2012:5 Pages 97 - 100 DOI: http://dx.doi.org/10.2147/IJNRD.S30194 Received: 25 January 2012 Accepted: 06 March 2012 Published: 15 June 2012 Teresa Olea,1 Raquel Díaz-Mancebo,1 Maria-Luz Picazo,2 Jorge Martínez-Ara,1 Angel Robles,3 Rafael Selgas,1 1Departments of Nephrology, 2Pathology, 3Internal Medicine, Hospital Universitario La Paz, Madrid, Spain Abstract: Interferon-beta is widely used for the treatment of relapsing multiple sclerosis. The drug is usually well tolerated, but autoimmune adverse effects, including kidney disease, have been reported. Only a few cases of hemolytic uremic syndrome-thrombotic microangiopathy associated interferon-alpha have been described so far, and even fewer with beta-interferon. We report a patient who developed thrombotic microangiopathy during treatment with interferon-beta and improved after discontinuation and steroid therapy. Complement cascade and antiphospholipid antibodies are investigated. The spectrum of renal diseases associated with interferon-beta treatment is also reviewed.